TINF2

Across TCGA pan-cancer cohorts, TINF2 mass-spec protein is linked to patient survival in 7 of 34 cancer types, making it a survival-associated TINF2 data layer compared with 21 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher TINF2 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated TINF2 expression acts as an unfavorable survival marker, although some lineages such as GBM and LUAD show a favorable association.

PDAC, GBM, and LUAD are the cancer types where TINF2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Median	All	0.199	0.533	.001	73	view →
GBM	OS	Tertile	All	0.690	0.366	.012	8	view →
LUAD	OS	Tertile	All	1.000	0.921	.016	8	view →
CCRCC	DFS	Median	All	1.000	0.730	.007	5	view →
HNSC	DFS	Tertile	IV	0.892	0.482	.049	4	view →
LSCC	OS	Median	II,III,IV	0.863	0.689	.040	3	view →
UCEC	OS	Quartile	All	1.000	0.840	.033	2	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

TINF2–PDAC (DFS)

Open the PDAC breakdown →